Expected Returns, October 2013

The methodology works. We take a look at your favorite stocks with a most widely-held update of the MANIFEST 40, how they've done over eight years and why we expect similar success from the next eight or 70 years.

Is Buy-and-Hold Dead? by Mark Robertson Oct 01, 2013

You don’t have to google very long to come up with a long list of articles and commentaries about the death of “buy and hold” as a strategy.

Teva Pharma by Mark Robertson Oct 01, 2013

TEVA is the largest generic drug manufacturing company in the world, and is focusing on building a stronger generic drug portfolio.

Hoard vs. Herds by Mark Robertson Oct 01, 2013

Accumulate Vanguard Technology

Sweet 16 by Mark Robertson Oct 01, 2013

Every week we sort through the update batch and feature companies with solid return forecasts according to Value Line. This month, we share the results of that screen.

Tin Cup Model Portfolio by Mark Robertson Oct 01, 2013

Accumulate Coach